RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Chronic myelomonocytic leukemia (CMML) is a clonal disorder of hematopoietic cells and is a complex of heterogeneous conditions with both myeloproliferative and myelodysplastic features. The diagnosis of CMML is made using morphologic criteria including monocyte-dominant leukocytosis, dysplastic changes, and increased blasts in the bone marrow. Recently, the identification of monocyte subtypes in peripheral blood using multiparameter flow cytometry has been actively studied. Chromosomal abnormalities are the basis of CMML risk stratification, and mutations in several genes including ASXL1 are known to be important not only for the diagnosis and treatment of this disease but also for predicting its prognosis. The standard treatment principles for CMML have not yet been clearly defined; however, hypomethylating agents are mainly considered the frontline therapy in most cases. Although allogeneic hematopoietic stem cell transplantation has limited applications owing to its toxicity, it still plays an important role as the only curative treatment option. Researchers are continuing to develop new drugs for CMML treatment and to prove their clinical usefulness. This review summarizes what is known to date on the diagnosis, treatment, and prognostic factors of CMML and presents future directions by analyzing recent research trends.

참고문헌 (Reference)

1 Ball M, "When clinical heterogeneity exceeds genetic heterogeneity : thinking outside the genomic box in chronic myelomonocytic leukemia" 128 : 2381-2387, 2016

2 Kongtim P, "Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia" 22 : 47-53, 2016

3 Santini V, "Treatment of low-risk myelodysplastic syndromes" 2016 : 462-469, 2016

4 Wong E, "Treatment of chronic myelomonocytic leukemia with azacitidine" 54 : 878-880, 2013

5 Thorpe M, "Treatment of chronic myelomonocytic leukemia with 5-Azacitidine : a case series and literature review" 36 : 1071-1073, 2012

6 Cargo C, "The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis" 133 : 1325-1334, 2019

7 Dinmohamed AG, "The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands" 39 : 177-182, 2015

8 Bennett JM, "The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British Cooperative Leukaemia Group" 87 : 746-754, 1994

9 Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" 127 : 2391-2405, 2016

10 Patnaik MM, "Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis" 91 : E12-E14, 2016